Viewpoints: Dual-blocking antibody against VEGF-A and angiopoietin-2 for treating vascular diseases of the eye: forum
Faricimab, a bispecific antibody that targets the endothelial cell growth factors vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2 (Angpt2), was recently approved for treating neovascular age-related macular degeneration and diabetic macular edema. Here, Koh and Augustin review how m...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) Editorial |
| Sprache: | Englisch |
| Veröffentlicht: |
May 2022
|
| In: |
Trends in molecular medicine
Year: 2022, Jahrgang: 28, Heft: 5, Pages: 347-349 |
| ISSN: | 1471-499X |
| DOI: | 10.1016/j.molmed.2022.03.004 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.molmed.2022.03.004 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S1471491422000727 
|
| Verfasserangaben: | Gou Young Koh, Hellmut G. Augustin, and Peter A. Campochiaro |
| Zusammenfassung: | Faricimab, a bispecific antibody that targets the endothelial cell growth factors vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2 (Angpt2), was recently approved for treating neovascular age-related macular degeneration and diabetic macular edema. Here, Koh and Augustin review how mechanistic studies have translated into therapies, while Campochiaro evaluates their impact and value for clinical practice. |
|---|---|
| Beschreibung: | Online verfügbar: 5 April 2022, Artikelversion: 28 April 2022 Gesehen am 26.02.2024 |
| Beschreibung: | Online Resource |
| ISSN: | 1471-499X |
| DOI: | 10.1016/j.molmed.2022.03.004 |